<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2280">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05131477</url>
  </required_header>
  <id_info>
    <org_study_id>KY1005-CT05</org_study_id>
    <secondary_id>2021-000725-28</secondary_id>
    <secondary_id>U1111-1271-1438</secondary_id>
    <secondary_id>DRI17366</secondary_id>
    <nct_id>NCT05131477</nct_id>
  </id_info>
  <brief_title>Study Testing Response Effect of KY1005 Against Moderate to Severe Atopic Dermatitis The STREAM-AD Study</brief_title>
  <official_title>A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kymab Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kymab Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind,&#xD;
      5-arm study to assess the effect of Anti-OX40L Monoclonal Antibody (KY1005) in adult&#xD;
      participants with moderate to severe atopic dermatitis.&#xD;
&#xD;
      The estimated duration is 4±1 weeks of screening and run-in period, followed by a 365 days&#xD;
      double blinded treatment period with additional 84 days safety follow-up up to Day 449.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 2, 2021</start_date>
  <completion_date type="Anticipated">May 20, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in EASI (Eczema Area and Severity Index) from Baseline</measure>
    <time_frame>Baseline to Day 113</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse event</measure>
    <time_frame>Baseline through Day 449</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum KY1005 concentration assessed throughout the study</measure>
    <time_frame>Baseline through Day 449</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change in EASI (Eczema Area and Severity Index) from baseline to Day 169</measure>
    <time_frame>Baseline to Day 169</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 75% reduction from Baseline in EASI (EASI 75)</measure>
    <time_frame>At Days 113 and 169</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with a response of IGA (Investigator Global Assessment) 0 or 1 and a reduction from baseline ≥ 2 points</measure>
    <time_frame>At Days 113 and 169</time_frame>
    <description>The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 2 is mild, 3 is moderate, and 4 indicates severe AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (reduction) of weekly average of pruritus NRS (Numerical Rating Scale) ≥ 4 with a baseline pruritus of ≥ 4 from baseline</measure>
    <time_frame>Days 113 and 169</time_frame>
    <description>The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute change from Baseline in EASI (Eczema Area and Severity Index)</measure>
    <time_frame>At Days 15, 29, 57, 85, 113, 141 and 169</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage change from Baseline in EASI (Eczema Area and Severity Index) At Days 15, 29, 57, 85 and 141</measure>
    <time_frame>At Days 15, 29, 57, 85 and 141</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 50% reduction from Baseline in EASI (EASI 50)</measure>
    <time_frame>At Days 15, 29, 57, 85, 113, 141 and 169</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of patients who reach at least a 75% reduction from Baseline in EASI (EASI 75)</measure>
    <time_frame>At Days 15, 29, 57, 85, and 141</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 90% reduction from Baseline in EASI (EASI 90)</measure>
    <time_frame>At Days 15, 29, 57, 85, 113, 141 and 169</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with at least a 100% reduction from Baseline in EASI (EASI 100)</measure>
    <time_frame>At Days 15, 29, 57, 85, 113, 141 and 169</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicate worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in IGA (Investigator Global Assessment)</measure>
    <time_frame>Day 169 and over time up to Day 365</time_frame>
    <description>The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 2 is mild, 3 is moderate, and 4 indicates severe AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate of patients with a score of IGA (Investigator Global Assessment) 0 or 1 and a reduction from Baseline of ≥ 2 points</measure>
    <time_frame>At Days 15, 29, 57, 85, and 141</time_frame>
    <description>The IGA is a five-point scale that provides a global clinical assessment of AD (Atopic Dermatitis) severity ranging from 0 to 4, where 0 indicates clear, 2 is mild, 3 is moderate, and 4 indicates severe AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and Percentage change in SCORAD (SCORing Atopic Dermatitis) Index from Baseline</measure>
    <time_frame>Baseline through Day 169 and over time up to Day 365</time_frame>
    <description>SCORAD was used to assess the extent and severity of AD (Atopic Dermatitis). Extent and severity of eczema as well as subjective assessment of symptoms were assessed and scored. SCORAD total score ranges from 0 (absent disease) to 103 (severe disease)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and Percentage change in Patient Oriented Eczema Measure (POEM) from Baseline</measure>
    <time_frame>Baseline to Day 169 and over time up to Day 365</time_frame>
    <description>POEM is a 7-item (dryness, itching, flaking, cracking, sleep loss, bleeding, and weeping) questionnaire to assess frequency of disease symptoms with a scoring system of 0 to 28. The higher score indicating higher severity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and Percentage change in Dermatology Life Quality Index (DLQI) from Baseline</measure>
    <time_frame>Baseline to Day 169 and over time up to Day 365</time_frame>
    <description>DLQI is a questionnaire with a score system of 0 to 30 the high score is indicative of poor QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and Percentage change in Atopic Dermatitis Control Tool (ADCT) from Baseline</measure>
    <time_frame>Baseline to Day 169 and over time up to Day 365</time_frame>
    <description>ADCT is a questionnaire to assess patient-self-perceived control of their eczema with a total score from 0 to 24; higher scores indicate lower AD control</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and Percentage change in Hospital Anxiety and Depression Scale (HADS) from Baseline</measure>
    <time_frame>Baseline to Day 169 and over time up to Day 365</time_frame>
    <description>HADS is a fourteen-item scale with seven items each for anxiety and depression subscales. Scoring for each item ranges from zero to three. A subscale score &gt;8 denotes anxiety or depression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute and Percentage change in weekly average of pruritus Numerical Rating Scale (NRS) from Baseline</measure>
    <time_frame>Baseline to Day 169 and over time up to Day 365</time_frame>
    <description>The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with improvement (reduction) of weekly average of pruritus NRS (Numerical Rating Scale) ≥ 3 with a baseline pruritus NRS ≥ 3 from baseline</measure>
    <time_frame>Baseline to Days 113 and 169</time_frame>
    <description>The pruritus NRS is a simple assessment tool to report the intensity of their pruritus (itch) ranges from 0 to 10 with 0 being 'no itch' and 10 being the 'worst itch imaginable'.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of positive anti-Ky1005 antibody response</measure>
    <time_frame>Baseline through Day 449</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of EASI 75</measure>
    <time_frame>Week 24 to Day 365</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of IGA 0/1 (Patients with a response of 0 or 1 in IGA)</measure>
    <time_frame>Week 24 to Day 365</time_frame>
    <description>The IGA is a five-point scale that provides a global clinical assessment of AD severity ranging from 0 to 4, where 0 indicates clear, 2 is mild, 3 is moderate, and 4 indicates severe AD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to loss of EASI 50</measure>
    <time_frame>Week 24 to Day 365</time_frame>
    <description>The EASI is a composite index with scores ranging from 0 to 72. Higher scores indicates worse condition.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Eczema</condition>
  <arm_group>
    <arm_group_label>KY1005 Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KY1005 Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KY1005 Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KY1005 Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KY1005</intervention_name>
    <description>Pharmaceutical form: Injection solution Route of administration: Subcutaneous</description>
    <arm_group_label>KY1005 Dose Level 1</arm_group_label>
    <arm_group_label>KY1005 Dose Level 2</arm_group_label>
    <arm_group_label>KY1005 Dose Level 3</arm_group_label>
    <arm_group_label>KY1005 Dose Level 4</arm_group_label>
    <other_name>Amlitelimab</other_name>
    <other_name>SAR445229</other_name>
    <other_name>A human anti-OX40 ligand monoclonal antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Injection solution Route of administration: Subcutaneous</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (18 to &lt; 75 years of age) with AD as defined by the American Academy of&#xD;
             Dermatology Consensus Criteria for 1 year or longer at Baseline.&#xD;
&#xD;
          -  EASI of 12 or higher at the Screening Visit and 16 or higher at Baseline.&#xD;
&#xD;
          -  IGA of 3 or 4 at Baseline.&#xD;
&#xD;
          -  AD involvement of 10% or more of body surface area (BSA) at Baseline.&#xD;
&#xD;
          -  Documented history, within 6 months prior to Baseline, of either inadequate response&#xD;
             or inadvisability of topical treatments.&#xD;
&#xD;
          -  Must have applied a stable dose of topical bland emollient (simple moisturiser, no&#xD;
             additives [e.g., urea]) at least twice daily for a minimum of 7 consecutive days&#xD;
             before Baseline.&#xD;
&#xD;
          -  Able and willing to provide written informed consent and comply with requested study&#xD;
             visits and procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent treatment within specific time windows before the baseline visit for the&#xD;
             management of atopic dermatitis such as topical or systemic corticosteroids, biologic&#xD;
             or investigational therapies and/or phototherapy.&#xD;
&#xD;
          -  Known history of or suspected significant current immunosuppression, including history&#xD;
             of invasive opportunistic infections despite infection resolution or otherwise&#xD;
             recurrent infections of abnormal frequency or prolonged duration.&#xD;
&#xD;
          -  Basal and squamous cell skin cancer in the last 3 years prior to Baseline. Any other&#xD;
             malignancies in the last 5 years prior to Baseline (excluding in situ cervical&#xD;
             carcinoma).&#xD;
&#xD;
          -  Severe concomitant illness that would in the Investigator's opinion inhibit the&#xD;
             patient's participation in the study, including for example, but not limited to, renal&#xD;
             disease, neurological conditions, heart failure and pulmonary disease.&#xD;
&#xD;
          -  In the Investigator's opinion, any clinically significant laboratory results from the&#xD;
             clinical chemistry, haematology or urinalysis tests at the Screening Visit.&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Concurrent participation in any other clinical study, including non-interventional&#xD;
             studies.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Trial Transparency email recommended(Toll free number for US and CAN)</last_name>
    <phone>1-800-633-1610</phone>
    <phone_ext>Option 6</phone_ext>
    <email>contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigative Site Number: 1018</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538-1601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1006</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33428</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1001</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756-3424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1019</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33134-2950</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1007</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176-2264</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1013</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33615-3816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1004</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406-2668</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1010</name>
      <address>
        <city>Clarksville</city>
        <state>Indiana</state>
        <zip>47129-2201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1015</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46250-2041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1011</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204-7448</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1014</name>
      <address>
        <city>Beverly</city>
        <state>Massachusetts</state>
        <zip>01915-1666</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1012</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084-3536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1002</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10455-4033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1005</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136-7049</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1017</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223-6683</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1009</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1003</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621-2062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1008</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130-2450</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1016</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78213-2250</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number 3002</name>
      <address>
        <city>Carlton</city>
        <zip>3053</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 3003</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number: 3001</name>
      <address>
        <city>Parkville</city>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2004</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2005</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2006</name>
      <address>
        <city>Sofia</city>
        <zip>1592</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2003</name>
      <address>
        <city>Sofia</city>
        <zip>1612</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2002</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2001</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1106</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1103</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K2C 3N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 1101</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 1E6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2108</name>
      <address>
        <city>Brno</city>
        <state>Jihomoravský Kraj</state>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2105</name>
      <address>
        <city>Nový Jicín</city>
        <state>Moravskoslezský Kraj</state>
        <zip>741 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2107</name>
      <address>
        <city>Pardubice</city>
        <state>Pardubický Kraj</state>
        <zip>530 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2101</name>
      <address>
        <city>Prague</city>
        <state>Praha, Hlavní Mesto</state>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2102</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavní Mesto</state>
        <zip>108 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2103</name>
      <address>
        <city>Praha</city>
        <state>Praha, Hlavní Mesto</state>
        <zip>130 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2106</name>
      <address>
        <city>Kutná Hora</city>
        <zip>284 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2104</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2209</name>
      <address>
        <city>Erlangen</city>
        <state>Bayern</state>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2202</name>
      <address>
        <city>Blankenfelde</city>
        <state>Brandenburg</state>
        <zip>15827</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigator Site Number: 2201</name>
      <address>
        <city>Münster</city>
        <state>Nordrhein-Westfalen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2205</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2206</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2208</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>2405</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2207</name>
      <address>
        <city>Gera</city>
        <state>Thüringen</state>
        <zip>4103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2203</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2204</name>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2307</name>
      <address>
        <city>Kecskemét</city>
        <state>Bács-Kiskun</state>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2305</name>
      <address>
        <city>Gyula</city>
        <state>Békés</state>
        <zip>5700</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2301</name>
      <address>
        <city>Szeged</city>
        <state>Csongrád</state>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2303</name>
      <address>
        <city>Debrecen</city>
        <state>Hajdú-Bihar</state>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2306</name>
      <address>
        <city>Szolnok</city>
        <state>Jász-Nagykun-Szolnok</state>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2302</name>
      <address>
        <city>Zalaegerszeg</city>
        <state>Zala</state>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2304</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2414</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>50-088</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2415</name>
      <address>
        <city>Lódz</city>
        <state>Lódzkie</state>
        <zip>90-127</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site number: 2408</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>30-033</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2407</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2409</name>
      <address>
        <city>Kraków</city>
        <state>Malopolskie</state>
        <zip>31-011</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site number: 2412</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>00-874</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site number: 2411</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-142</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2413</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-192</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2401</name>
      <address>
        <city>Rzeszów</city>
        <state>Podkarpackie</state>
        <zip>35-055</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2402</name>
      <address>
        <city>Gdańsk</city>
        <state>Pomorskie</state>
        <zip>80-382</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2404</name>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <zip>81-384</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2405</name>
      <address>
        <city>Katowice</city>
        <state>Slaskie</state>
        <zip>40-040</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2410</name>
      <address>
        <city>Szczecin</city>
        <state>Zachodniopomorskie</state>
        <zip>71-434</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ivestigative Site Number: 2403</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-592</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2406</name>
      <address>
        <city>Krakow</city>
        <zip>31-559</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2502</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2505</name>
      <address>
        <city>Alicante</city>
        <zip>3010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2501</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2503</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2504</name>
      <address>
        <city>Pontevedra</city>
        <zip>36001</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 3201</name>
      <address>
        <city>Niao Song Qu</city>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 3202</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 3203</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2603</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Number: 2601</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigative Site Numbers: 2602</name>
      <address>
        <city>Sheffield</city>
        <zip>S10 2TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>November 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 23, 2021</study_first_posted>
  <last_update_submitted>December 9, 2021</last_update_submitted>
  <last_update_submitted_qc>December 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

